Linked Life Data

21178282

Source:http://linkedlifedata.com/resource/pubmed/id/21178282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-12-23
pubmed:abstractText
Bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and prevents tumor angiogenesis. Radionuclide imaging using radiolabeled bevacizumab might be useful for selection of patients for anti-VEGF therapy. This study describes preparation of a potential imaging agent, 111In-CHX-A"-DTPA-bevacizumab, and evaluation of specificity of its binding to three tumor cell lines, SKOV3, LS174T and DU 145. Bevacizumab was conjugated with CHX-A"-DTPA and radiolabeled with 111In with high yield and excellent stability. Specificity of cellular binding was examined by a saturation assay using 100-fold excess of non-radiolabeled antibody. SKOV3 and LS174T tumor cell lines showed significantly specific binding, while DU 145 cells did not showed any specific binding. The specific binding is dependent to type of cell lines, which it is important for selection of tumor model for scintigraphic imaging of the VEGF expression.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1875-869X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
107-11
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab.
pubmed:affiliation
Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. jhosseinim@yahoo.com
pubmed:publicationType
Journal Article, Evaluation Studies